Non-small-cell lung carcinoma

Ocean Biomedical Provides Corporate Update and Company Summary

Retrieved on: 
Tuesday, January 24, 2023
Benchmark, Disease, Infection, Hermansky–Pudlak syndrome, Pulmonary fibrosis, Scleroderma, Lung cancer, SPAC, Research, Brown University, Fibrosis, Malaria, Yale University, Technology transfer, Glioblastoma, Harvard University, Non-small-cell lung carcinoma, Business architecture, Biomedicine, Nelson Mullins Riley & Scarborough, Stanford University, Prevalence, NSCLC, NASH, HPS, Tuberculosis, Brain, CHI3L1, Alcoholic liver disease, Idiopathic pulmonary fibrosis, Human, Acquisition, Cancer, LLP, Risk, Dykema Gossett, RI, EF Hutton, GBM, Patient, Growth, Pharmaceutical industry, Vaccine

PROVIDENCE, RI and NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“Ocean”), a next-generation biopharma company, and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA), a publicly traded special purpose acquisition company (SPAC), shared today an update on key company activities. Built on Ocean Biomedical’s expertise in technology transfer, a unique business model was created to bridge the ‘bench-to-bedside’ gap and accelerate the commercialization of novel assets from leading research universities and medical centers. Ocean Biomedical is expected to become a publicly traded company on NASDAQ under the symbols “OCEA” and “OCEAW” following the expected closing of a Business Combination with Aesther Corporation.

Key Points: 
  • PROVIDENCE, RI and NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“Ocean”), a next-generation biopharma company, and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA), a publicly traded special purpose acquisition company (SPAC), shared today an update on key company activities.
  • Ocean Biomedical is expected to become a publicly traded company on NASDAQ under the symbols “OCEA” and “OCEAW” following the expected closing of a Business Combination with Aesther Corporation .
  • “The scientific and operational progress Ocean Biomedical has had to date, even without access to the public markets, is astounding – the company is at an inflection point, with multiple ways to win.
  • Each of these assets are progressing towards the next stage of their development pipelines,” said Dr. Chirinjeev Kathuria, Ocean Biomedical co-founder and Executive Chairman of the Board of Directors.

PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Memory, Peptide, Melanoma, Blood bank, PBMC, HLA-A2, B cell, Antigen, Large-cell lung carcinoma, NK, Poster, MUC1, Patient, NY-ESO-1, PDC, Lung cancer, Hlas, GMP, Non-small-cell lung carcinoma, PD-1, RECIST, White blood cell, Safety, Cancer, Dendritic cell, ESMO, Human, RNA transfection, LOQ, Clinical trial, Growth, Bioreactor, MAGE, EFS, Pembrolizumab, Mutation, Pharmaceutical industry, Vaccine, NSCLC

The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).

Key Points: 
  • The preliminary data was presented today at a poster display session at the ESMO Immuno-Oncology Congress 2022 (ESMO-IO) in Geneva (Switzerland).
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • It is administered weekly by a subcutaneous and intravenous route, in six consecutive doses.
  • Safety and clinical activity of the product were presented at ESMO 2022 in September 2022 in Paris (France).

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Syngenic, Immune system, NSCLC, Congress, Non-small-cell lung carcinoma, Glioblastoma, RCC, RNA, Cancer, IND, Large-cell lung carcinoma, SCLC, Renal cell carcinoma, Squamous cell carcinoma, Patient, Melanoma, Burn, SVV, Annual report, EGFR, Workforce, Genome, Wilms' tumor, Senecavirus, Nature Communications, Security (finance), GEMM, Mouse, HCC, Hepatocellular carcinoma, IV, RNA transfection, CVA21, Immunotherapy, Investment, Safety, Vaccine, Pharmaceutical industry, PDX, LNP

As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.

Key Points: 
  • As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.
  • Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023.
  • ONCR-021 is Oncorus lead candidate from its self-amplifying RNA platform intended to allow for intravenous (IV) administration.
  • At Oncorus, we are focused on driving innovation in RNA medicines by developing next-generation immunotherapies to stimulate the immune system and transform outcomes for cancer patients.

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Retrieved on: 
Monday, November 7, 2022
Drug, MRC Laboratory of Molecular Biology, Laboratory, Neoplasm, NCI, National, Physician, Cooperative research and development agreement, Molecular biology, Cancer, Non-small-cell lung carcinoma, Engineering, Development, CRADA, HIO, Patient, Triple-negative breast cancer, Program, Pharmaceutical industry, Vaccine, Thorax

PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.

Key Points: 
  • PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.
  • Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate, NAV-001, under the supervision of Dr. Raffit Hassan, Chief of Thoracic and GI Malignancies Branch at the NCI.
  • "NAV-001 has proven to be very effective with single, sub-mg/kg dosing against various patient-derived tumor types in mouse models, causing significant regression of the cancer lesions."
  • Navrogen is a biotechnology company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that are associated with suppressed humoral immunity, poor prognosis and limited therapeutic response of immune-mediated anti-cancer therapies.

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Genentech, Peripheral neuropathy, Journal, Private Securities Litigation Reform Act, Phase, Therapy, Neck, Medicinal chemistry, CD137, Biotechnology, MT1-MMP, BTC, Incidence, U.S. Securities and Exchange Commission, Toxic leukoencephalopathy, Journal of Medicinal Chemistry, COVID-19, Esophageal cancer, Ovary, Head, Research, Molecular Cancer Research, Rash, Clinical trial, Cancer research, Forward-looking statement, Cancer, NASDAQ, American Association for Cancer Research, Non-small-cell lung carcinoma, Drug development, Risk, Program, Technology, Security (finance), Thromboxane A2, SEC, Treatment, Patient, Triple-negative breast cancer, Pharmaceutical industry, Bicycle

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
  • We are encouraged by the continued clinical progress across our pipeline, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2, in patients with advanced solid tumors.
  • In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial.

Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022
U.S. Securities and Exchange Commission, SEC, PD, IND, DTC, Non-small-cell lung carcinoma, NASDAQ, ENA, Research and development, Patient, Neoplasm, Security (finance), PDX, KIT, GIST, Cancer, D, Private Securities Litigation Reform Act, Lung cancer, Company, LTC, NSCLC, TKI, CNS, Recurrence, Survival, Brain, Forward-looking statement, Theseus, LC, Exon, Risk, Large-cell lung carcinoma, Pharmaceutical industry, Vaccine, Medical imaging, EGFR, Research, T790M

CAMBRIDGE, Mass., Oct. 26, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced preclinical data characterizing its fourth-generation epidermal growth factor receptor (EGFR) inhibitor, THE-349, will be detailed in a live poster presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (ENA), taking place in Barcelona, Spain on October 26 – 28, 2022. THE-349 is currently in preclinical development as a single-molecule inhibitor of all major classes of EGFR activating and resistance mutations consisting of single-, double- and triple-mutant EGFR variants, including T790M and C797X, for treatment of EGFR-mutant non-small cell lung cancer (NSCLC).

Key Points: 
  • "We are pleased to share preclinical data characterizing THE-349, our newly nominated fourth-generation EGFR inhibitor," said William Shakespeare, Ph.D., President of Research and Development at Theseus.
  • These preclinical data demonstrate that THE-349, as a single agent, exhibits highly potent inhibition of all major EGFR mutant variants with a high degree of kinome and wild-type EGFR selectivity.
  • The activity profile achieved by THE-349 positions the asset for development as a single agent and potentially in combination with other, non-EGFR inhibitor modalities.
  • Deep and/or complete tumor regression in an osimertinib-resistant, patient-derived (PDX) NSCLC model harboring heterogeneous EGFR mutant variants (D and DTC).

Global PD-1/PDL-1 Inhibitor Market Report 2022: Increased Use of PD-1/PDL-1 Inhibitors in Multiple Sub-set of Cancer Indications Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 22, 2022
Biotechnology, Pharmaceutical, Health, MSD, Dostarlimab, Research report, Precision medicine, Squamous cell carcinoma, Neoplasm, Colorectal cancer, Face, GSK, Melanoma, Patient, Region, Breast cancer, Non-small-cell lung carcinoma, BMS, PD-L1, Research, Bristol Myers Squibb, PD-1, AstraZeneca, HIV disease progression rates, Merck, Hepatocellular carcinoma, Palladium, Pharmaceutical industry, Marketing, Epidemiology

The "PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PD-1/PDL-1 Inhibitor Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The first PD-1 inhibitor Opdivo developed by Merck Sharp and Dhome (MSD) entered the market in 2014.
  • PD-1/PDL-1 inhibitors are majorly indicated for the treatment of advanced cases of different cancer indications.
  • Some of the potential drivers identified by the publisher includes:
    The market is expected to face some limitations too due to the following challenges:

United States Non-Small Cell Lung Cancer Market Research and Competitive Landscape Report 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022
Health, General Health, Research, Competitive landscape, Epidemiology, Non-small-cell lung carcinoma, Prevalence, Patient, Uranium, Pharmaceutical industry, Medical imaging, Antibiotics, Platinum

The "US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Non-Small Cell Lung Cancer Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insights into Non-Small Cell Lung Cancer pipeline products, Non-Small Cell Lung Cancer epidemiology, Non-Small Cell Lung Cancer market valuations and forecast, Non-Small Cell Lung Cancer drugs sales and competitive landscape in the US.
  • Non-Small Cell Lung Cancer pipeline: Find out the products in clinical trials for the treatment of Non-Small Cell Lung Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Non-Small Cell Lung Cancer epidemiology: Find out the number of patients diagnosed (prevalence) with Non-Small Cell Lung Cancer in the US
    Non-Small Cell Lung Cancer drugs: Identify key products marketed and prescribed for Non-Small Cell Lung Cancer in the US, including trade name, molecule name, and company
    Non-Small Cell Lung Cancer drugs sales: Find out the sales revenues of Non-Small Cell Lung Cancer drugs in the US
    Non-Small Cell Lung Cancer market valuations: Find out the market size for Non-Small Cell Lung Cancer drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Non-Small Cell Lung Cancer drugs market share: Find out the market shares for key Non-Small Cell Lung Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Non-Small Cell Lung Cancer products
    1.

Kiyatec CEO Matt Gevaert joins biopharma leaders and healthcare investor discussions at Longwood Healthcare Leaders Fall Webconference

Retrieved on: 
Tuesday, September 13, 2022
Research, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Breast, Acceleration, 3D, Organic, Drug, Ovarian cancer, Neoplasm, Company, Patient, Chief executive officer, Multimedia, Non-small-cell lung carcinoma, Pharmaceutical industry

Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced that CEO Matt Gevaert, Ph.D., will participate as a panelist in the Accelerating Drug Development session at the Longwood Healthcare Leaders Fall Webconference on Thursday, September 22, 2022, at 8:50 AM Eastern Time.

Key Points: 
  • Kiyatec, the leader in clinically correlated, published functional precision oncology evidence today announced that CEO Matt Gevaert, Ph.D., will participate as a panelist in the Accelerating Drug Development session at the Longwood Healthcare Leaders Fall Webconference on Thursday, September 22, 2022, at 8:50 AM Eastern Time.
  • Details regarding this and future Longwood Healthcare Leaders events can be found at https://www.longwoodhealthcareleaders.com/ .
  • The Longwood Healthcare Leaders conferences serve to facilitate the acceleration of life sciences discoveries to benefit patients.
  • The Company is accelerating its commercial and business development services while securing payer pricing, coverage and reimbursement.

PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022

Retrieved on: 
Tuesday, September 13, 2022
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Science, Oncology, MUC1, Safety, Memory, Blood bank, RNA transfection, Bioreactor, Hlas, Hope, Data monitoring committee, KU Leuven, Population, European Society for Medical Oncology, Growth, Progression-free survival, NY-ESO-1, Melanoma, MAGE, Lung cancer, Patient, Degenerative disease, RECIST, CEO, Dendritic cell, Technology, Oncology, DLT, Large-cell lung carcinoma, SAE, PDC, EFS, PD-L1, PD-1, Mutation, Cancer, PBMC, GMP, B cell, Non-small-cell lung carcinoma, ESMO, Pharmaceutical industry, Vaccine, A2, NSCLC, A1

The preliminary data was presented today at a poster discussion session at the 2022 European Society for Medical Oncology (ESMO) Annual Meeting.

Key Points: 
  • The preliminary data was presented today at a poster discussion session at the 2022 European Society for Medical Oncology (ESMO) Annual Meeting.
  • The objectives of the phase I/II trial (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated with, or not, anti-PD-1 treatment in NSCLC patients.
  • Results are reported on the first three cohorts that have been completed (A1/A2/B1).
  • With preliminary clinical data now available from patients of the first three enrolled cohorts, it is encouraging to see PDC*lung01 as safe, immunogenic and to have signs of clinical efficacy.